Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizoaffective Disorder
BXCL501 for Agitation in Schizophrenia
Agitation is characterized by excessive motor or verbal activity, irritability, uncooperativeness, threatening gestures, and, in some cases, aggressive or violent behavior.
- Trial name
- DEX (NCT03708315)
- Testing
- Dexmedetomidine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Tetrabenazine for Partial Responders
Purpose of Study: A) To improve outcome in large population of antipsychotic patients with schizophrenia or schizoaffective who are only partial responders B) To increase understanding of pharmacology and mechanisms of action…
- Trial name
- NCT00362804
- Testing
- Tetrabenazine
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
The purpose of the study is to compare the effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) versus placebo for the treatment of the symptoms of schizophrenia over a…
- Trial name
- NCT00253136
- Testing
- risperidone
- Volunteers
- 458 people
- Sponsor
- Janssen, LP
Schizophrenia Disorders, Chronic Illness
Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)
Policy makers and consumers are increasingly concerned about the quality and efficiency of care provided to individuals with severe, chronic illnesses such as schizophrenia.
- Conditions
- Schizophrenia Disorders, Chronic Illness, Schizoaffective Disorder, Weight Gain
- Trial name
- NCT00119574
- Testing
- Collaborative Chronic Illness Model
- Where
- United States
- Volunteers
- 443 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Once Weekly D-cycloserine for Schizophrenia
This is a parallel-group, placebo-controlled trial examining the cognitive effects at weeks 1, 4, \& 8 of once-weekly oral D-cycloserine 50 mg added to a stable dose of antipsychotic for 8 weeks in adult outpatients with…
- Trial name
- NCT00964041
- Testing
- D-cycloserine
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia
This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial of curcumin for the treatment of cognitive impairment in schizophrenia.The primary aim of this pilot trial is to provide an…
- Trial name
- CRC (NCT02476708)
- Testing
- curcumin 1800mg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or…
- Trial name
- NCT00231335
- Testing
- escitalopram
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Schizophrenia / Schizoaffective Disorder
The Effect of Structured Medical Nutrition Therapy on Systemic Inflammation Index in Patients With Schizophrenia Receiving Antipsychotic Therapy
Patients with schizophrenia receiving long-term antipsychotic therapy are at increased risk of chronic low-grade inflammation and metabolic disturbances, which contribute to poor physical health outcomes and increased…
- Trial name
- NCT07696000
- Testing
- Modification Diet, Hospitalized Diet
- Where
- Indonesia
- Volunteers
- 100 people
- Sponsor
- DINA KEUMALA SARI
Schizophrenia, Pediatric
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT04779177
- Testing
- Lumateperone 42 mg, Lumateperone 28 mg
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia or Schizoaffective Disorder
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
The objective of this study is to evaluate predictors of response to antipsychotic medication in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI, genetics and neuropsychological profile.
- Trial name
- NCT01016145
- Testing
- Antipsychotics
- Where
- Brazil
- Volunteers
- 126 people
- Sponsor
- University of Sao Paulo
Schizophrenia, Schizoaffective Disorder
Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia
This research project focuses on a fundamental element of the psychopathology of schizophrenia, that is to say, the disorders of self-awareness and on the functional alterations associated with it, that is to say, self-compassion…
- Trial name
- SCE-SCHIZO (NCT05464563)
- Testing
- Electroencephalogram
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Henri Laborit
Bipolar Disorder, Schizoaffective Disorder
Effects of Pentazocine Versus Lorazepam on Manic Symptoms
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals. To follow up these initial findings, we plan to conduct a larger, more rigorous, double-blind study.
- Conditions
- Bipolar Disorder, Schizoaffective Disorder, Manic Disorder, Mania
- Trial name
- NCT00431184
- Testing
- Pentazocine, Lorazepam
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mclean Hospital
Schizophrenia / Schizoaffective Disorder, Depression / Major Depressive Disorder
Brain Imaging of Cognition Inn Schizophrenia and Depression
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining…
- Trial name
- NCT04159662
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia
Lithium Drug-Drug Interaction Study With Lurasidone HCl
The purpose of this study is to evaluate the drug-drug interaction effect between Lithium and Lurasidone HCl.
- Trial name
- NCT01074073
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorders
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
- Trial name
- NCT01082588
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizoaffective Disorder
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. This may lead to worsening of symptoms.
- Trial name
- NCT00215579
- Testing
- Depot Risperidone Microsphere (Consta)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Duke University
Schizophrenia, Schizo Affective Disorder
Financial Incentives to Improve Acceptance of Antipsychotic Injections
There is a lack of incentive approach for patients who suffer from schizophrenia yet lack the insight to accept treatment. Most existing approaches involve coercion and involuntary hospitalizations.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- NCT03192631
- Testing
- Financial incentive
- Volunteers
- 20 people
- Sponsor
- Focus Community Mental Health Team
Schizophrenia, Psychosis
Glutamate, Brain Connectivity and Duration of Untreated Psychosis
The early stages of schizophrenia are associated with significant decreases in social and intellectual abilities, with more declines in chronic disease.
- Conditions
- Schizophrenia, Psychosis, Schizoaffective Disorder
- Trial name
- DUP (NCT02034253)
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Schizophrenia, Schizoaffective Disorder
Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy
A study to examine whether an antipsychotic combination treatment of olanzapine and amisulpride is more effective than olanzapine and amisulpride alone.
- Trial name
- COMBINE (NCT01609153)
- Testing
- Olanzapine, Amisulpride, Olanzapine and Amisulpride
- Where
- 21 sites in Germany
- Volunteers
- 328 people
- Sponsor
- Heinrich-Heine University, Duesseldorf